Insulin autoimmune syndrome in an Argentine woman taking α-lipoic acid: A case report and review of the literature

Valentina Izzo, Carla Greco, Diana Corradini, Marco Infante, Maria Teresa Staltari, Maria Romano, Alfonso Bellia, Davide Lauro and Luigi Uccioli

Abstract
Insulin autoimmune syndrome is an unusual cause of spontaneous hypoglycaemia in non-Asian populations. In the majority of cases, this syndrome appears a few weeks after the administration of drugs containing a sulfhydryl group. A strong association between this syndrome and HLA-DR4 has been shown. Only seven cases have been described in non-Asian patients. We report the first case of insulin autoimmune syndrome in an Argentine woman taking alpha-lipoic acid. She developed hypoglycaemic symptoms approximately 1 month after starting therapy. Blood sampling collected during an episode of symptomatic hypoglycaemia showed low blood glucose level (2.39 mmol/L), high level of serum insulin (1971.55 pmol/L), inappropriately high level of C-peptide (2.36 nmol/L) and high levels of insulin antibodies (274.78 IU/mL). HLA-DNA typing identified DRB1*04:03. Due to the widespread use of alpha-lipoic acid for its antioxidant properties, clinicians should be aware that it may trigger an autoimmune hypoglycaemia in people with a genetic predisposition.

Keywords
Insulin autoimmune syndrome, alpha-lipoic acid, hypoglycaemia, Hirata disease, antibodies

Introduction
The Hirata disease, also known as insulin autoimmune syndrome (IAS), is an unusual cause of hypoglycaemia characterized by high serum levels of insulin and a significant increase of endogenous antibodies which bind insulin/proinsulin and/or insulin receptor.1-3

Described by Yukimasa Hirata in 1972,4 IAS is the third commonest cause of spontaneous hypoglycaemia in Japan, after Insulinoma and extrapancreatic tumours.5

IAS is closely related with HLA-DR4. In the Japanese population, HLA DRB1*04:06 and DRB1*04:03 (at lower level) are the alleles most frequently found in this clinical pattern.6

Viral infections7 and drugs composed of sulphur/sulfhydryl groups such as methimazole,8 captopril, D-penicillamine, mercaptans, clopidogrel, imipenem, albumin and diltiazem have been considered as the potential factors inducing IAS.9

In several cases, IAS has been described in patients affected by other autoimmune disorders, such as autoimmune thyroiditis, membrano-proliferative glomerulo-nephritis and rheumatoids arthritis.10-13

In 2003, at the Kyushu local meeting of the Japan Diabetes Society, Hashinaga T. et al. reported a clinical case of IAS due to an additional sulfhydryl drug defined α-lipoic acid (ALA). In the recent years, an increase in cases of ALA-induced IAS has been described. IAS related to ALA administration has been reported most frequently in Japanese and Koreans subjects. Recently, seven new cases have been described in Italian patients.

We report a case of IAS induced by ALA in an Argentine woman who referred to our Department.

Furthermore, we provide a literature review of all the cases of IAS due to ALA administration, in order to open a comprehensive overview of the characteristics of this unusual disease.

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

Corresponding Author:
Valentina Izzo, Department of Systems Medicine, University of Rome Tor Vergata, 00133, Rome, Italy.
Email: valentina_izzo@virgilio.it
Case

A 66-year-old female referred to the Emergency Room for malaise and sweating. Laboratory findings showed low blood glucose level (2.56 mmol/L). She was admitted to our Department to study deeply the cause of hypoglycaemia. Informed consent was obtained.

Her clinical anamnesis was negative. Recently, due to joint pain, she started therapy with ALA (800 mg/day) for 1 month and, after a suspension of 15 days, she further continued for 10 days. Two weeks before the admission in our hospital, she discontinued this therapy due to repeated episodes of hand tremor and hunger that appeared 3–4 h after a meal. Furthermore, these symptoms regressed after sugar ingestion.

There was no family history of autoimmune or endocrine disorders.

The body weight was 72.55 kg and height was 170 cm (Body Mass Index 25.1 kg/m²). At admission, heart rate was 84/min and blood pressure 120/80 mmHg. The patient was conscious and oriented. Clinical chest and heart exams were negative. She had no thyroid goitre, acanthosis, skin tags or clinical and serological evidence of underlying autoimmune disease. Neurological findings were normal.

Laboratory values showed normal results except for blood glucose levels: 3.8 mmol/L (n.v. 4.0–5.9 mmol/L), high level of serum insulin: 1116.5 pmol/L (n.v. <174 pmol/L), inappropriately high level of C-peptide (1.81 nmol/L, n.v. 0.3–2.36). Table 1 shows laboratory data on admission.

An oral glucose tolerance test performed over 240 min showed basal glucose value of 3.88 mmol/L, a peak of 6.9 mmol/L at 120 min and a nadir of 2.33 mmol/L at 240 min.

Therefore, we performed enzyme immunoassay to obtain a quantitative determination of IgG autoantibodies to insulin in human serum (MediZym, Autoantibodies to Insulin ELISA Assay Kit, MEDIPAN). High titre of insulin antibodies (271 U/mL, n.v. <0.4) had been detected.

We repeated blood sampling during a symptomatic episode of hypoglycaemia that confirmed the above-mentioned data: low blood glucose level (2.39 mmol/L), high levels of serum insulin (1971.55 pmol/L), inappropriately high levels of C-peptide (2.36 nmol/L) and high levels of insulin antibodies (274.78 IU/mL).

The 72-h fasting test was not performed due to the need for intravenous glucose support during the repeated and frequent hospital episodes of hypoglycaemia.

Abdominal computer tomography and Octreoscan scintigraphy excluded the presence of Insulinoma.

HLA-DNA typing identified DRB1*04:03.

Discussion

In most cases, IAS appears a few weeks after the administration of a drug containing sulphydryl group.

The reducing activity of these compounds promotes the dissociation of the insulin S-S binding and exposes the insulin α chain to the antigen-presenting cells.14

The amino acid sequence Ile-Leu-Gln, contained in the insulin α chain, has a strong affinity for DRB1*04:06 molecule.14 Another peptide localized from no.8 to no.17 of the insulin α chain (TSICSLYQLE) shows a high affinity with this molecule. This amino acid sequence is able to stimulate the T cells of DRB1*04:06-positive patients, leading to the synthesis of polyclonal insulin autoantibodies.14,15

In 2003, Hashinaga T. et al. reported an IAS clinical case due to an additional sulphydryl drug, namely ALA.

ALA, also called thioctic acid, is a compound with a strong reductive effect.16

The antioxidant properties of α-lipoic acid play an essential role in the treatment of diabetic peripheral neuropathic pain.17 It is well known that the overproduction of reactive oxygen species is a common factor in the pathogenesis of atherosclerosis, diabetes mellitus and hypertension.

Furthermore, ALA is widely used as a health supplement for dieting and antiaging. In the past 20 years, ALA is often used as a dietary supplement in Japan. In these years, several cases of IAS have been reported and, after methimazole, ALA has been considered the main cause of this syndrome.18 Table 2 shows a summary of ALA-induced IAS cases described from 2003 to May 2018.13,18–23 The majority of cases reported in the table have been presented exclusively in scientific meetings. Overall, 27 cases of Hirata disease due to ALA administration has been documented: 18 in Japan, 7 in Italy and 2 in Korea. In 23 patients, HLA-DNA typing has been reported. A total of 13 of 17 Asiatic patients had the HLA-DRB1*04:06 allele compared with only 3 Asiatic patients with DRB1*04:03. All Caucasian patients were Italian, in six of those HLA-DRB1*04:03 was identified while HLA-DRB1*04:06 was isolated in two cases.

We describe the case of an Argentine woman presenting episodes of hypoglycaemia related to the ingestion of ALA. The association of hypoglycaemia with extremely high levels of serum insulin was indicative of IAS.

Laboratory test showed inappropriately high level of C-peptide. It may be related to the cross-reactivity between C-peptide and proinsulin which may be immunologically counted and reported as ‘free C-peptide’.1,24,25

Although in the reported cases the syndrome occurs mainly with neuroglycopenic symptoms, our patient experienced adrenergic symptoms that occurred 2–3 h after a meal. As reported in the scientific literature, also in our patient the symptoms appeared more than a month after starting therapy and disappeared spontaneously after 1 month of drug withdrawal.
Table 1. Results of laboratory test on admission.

| Analyte                                | Patient’s value | Reference range         |
|----------------------------------------|-----------------|-------------------------|
| Red blood count (×10⁶)                  | 4.6             | (3.5–5.2)               |
| Haemoglobin (gr/dL)                    | 13.4            | (12–16)                 |
| Haematocrit (%)                        | 41.3            | (34.5–52)               |
| White blood count (/mm³)               | 9.830           | (4.3–10.8)              |
| Platelet count (×10⁹)                  | 335             | (150–450)               |
| Creatinine (μmol/L)                    | 63.64           | (48.62–97.24)           |
| Blood urea nitrogen (mg/dL)            | 46              | (15–50)                 |
| Uric acid (mg/dL)                      | 3.7             | (2.4–5.7)               |
| Sodium (mEq/L)                         | 140             | (133–145)               |
| Potassium (mEq/L)                      | 4.8             | (3.3–5.1)               |
| Albumin (gr/L)                         | 30              | (34–48)                 |
| Aspartate aminotransferase (IU/L)      | 18              | (6–24)                  |
| Alanine aminotransferase (IU/L)        | 35              | (13–45)                 |
| γ-glutamyl transpeptidase (IU/L)       | 62              | (5–55)                  |
| C-reactive protein (mg/L)              | <0.100          | (0–3)                   |
| Tissue transglutaminase antibodies (IgA; IU/mL) | 2.02 | (<9) |
| Deamidated gliadin peptide antibodies (IgG; IU) | <2.8 | (<20) |
| Deamidated gliadin peptide antibodies (IgA; IU) | <5.2 | (<20) |
| Anti-endomysial antibodies (IgG)       | Negative        |                         |
| Anti-endomysial antibodies (IgA)       | Negative        |                         |
| Anti-adrenal antibodies                | Negative        |                         |
| Anti-TPO antibodies (kIU/L)            | 15              | (0–35)                  |
| Anti-insulin antibodies (UI/mL)        | 271             | (0–0.40)                |
| Fasting plasma glucose (mmol/L)        | 3.8             | (4–5.9)                 |
| Immunoreactive insulin (pmol/L)        | 1116.50         | (21.52–143.5)           |
| C-peptide (nmol/L)                     | 1.81            | (0.3–2.36)              |
| HbA1c (mmol/mol)                       | 39              | (23–42)                 |
| Prolactin (nmol/L)                     | 0.38            | (0.122–1.27)            |
| TSH (mIU/L)                            | 3.13            | (0.35–4.5)              |
| ACTH (pmol/L)                          | 5.08            | (0–10.12)               |
| i-PTH (pmol/L)                         | 4.8             | (1.49–7.64)             |
| 25-OH-Vitamin D (nmol/L)               | 61.4            | (>74.88)                |
| GH (μg/L)                              | 2.0             | (0.01–10)               |

TSH: thyroid-stimulating hormone; TPO: thyroperoxidase; ACTH: adrenocorticotrophic hormone; i-PTH: intact-parathyroid hormone; GH: growth hormone; HbA1c: glycated haemoglobin.

Figure 1. Blood glucose, serum insulin levels and antibodies titre during the hospitalization and follow-up period.
HLA-DNA typing identified DRB1*04:03. This finding confirms the implication of this allele in the genetic IAS predisposition also in not Asian population.

In our opinion, it is very suggestive that IAS related to ALA has been only described in the Asian population and in some Italian patients. The ‘Allele Frequency Net Database’ documented that HLADRB1*04:06 has a high prevalence in the Japanese population (allele frequency: 0.0339) while it is less common in Italy (allele frequency: 0.001).\(^2\) HLADRB1*04:03 is common among Caucasians and the allele frequency in Italy and Argentine are, respectively, 0.01 and 0.014. Nevertheless, analysing the allele frequency distribution, in countries with a similar prevalence of HLADRB1*04:03 and common use of ALA (Germany, United States, etc.), no cases of Hirata disease related to ALA have been reported.

This epidemiological data is very interesting, although we have not clear evidence to explain it. In our opinion, there are some promoting or protective factors (genetic? environmental?) which can induce or switch off this autoimmune reaction. This aspect needs to be deeply investigated.

In our patient, hypoglycemic symptoms appeared more than a month after starting therapy and disappeared spontaneously after 1 month of drug withdrawal. After drug suspicion, the most effective therapy is usually the ingestion of several small amounts and avoiding meals with high glycaemic index carbohydrates. Otherwise, some patients required pharmacological intervention as alpha-glucosidase, corticosteroids, immunosuppressant and plasmapheresis. Alpha-glucosidase inhibitors, such as acarbose, delay the absorption of glucose, decreasing the hypersecretion of insulin.\(^2\) Another possible therapy is corticosteroids.\(^8\) Immunosuppressants and plasmapheresis may be used in not responsive patients.\(^1\)

### Table 2. α-lipoic acid-induced insulin autoimmune syndrome reported from 2003 to December 2016.

| No. | Age | Sex | Insulin (pmol/L) | Country | Author            | Year | HLA-DRB1 |
|-----|-----|-----|------------------|---------|-------------------|------|----------|
| 1   | 55  | F   | 58.47            | Japan   | Hashinaga et al.  | 2003 | 0406     |
| 2   | 44  | F   | 3860.15          | Japan   | Furukawa et al.   | 2006 | 0406     |
| 3   | 67  | F   | 5646.73          | Japan   | Kamiya et al.     | 2006 | −        |
| 4   | 66  | F   | 4735.5           | Japan   | Nishikawa et al.  | 2006 | 0406     |
| 5   | 49  | F   | 1722†            | Japan   | Takanashi et al.  | 2006 | 0406     |
| 6   | 34  | F   | 2870             | Japan   | Yoshioka et al.   | 2006 | 0406     |
| 7   | 64  | F   | 904              | Japan   | Kurashiki et al.  | 2006 | DR4      |
| 8   | 32  | F   | 3.860            | Japan   | Ishida et al.     | 2007 | 0406     |
| 9   | 34  | F   | 3716.65          | Japan   | Nakajima et al.   | 2007 | 0406     |
| 10  | 55  | M   | 18.16            | Japan   | Takeuchi et al.   | 2007 | 0406     |
| 11  | 36  | F   | 464.94           | Japan   | Yoshida et al.    | 2007 | −        |
| 12  | 35  | M   | 13.95            | Japan   | Sasaki et al.     | 2007 | 0406     |
| 13  | 36  | F   | 7139.13          | Japan   | Ogou et al.       | 2007 | −        |
| 14  | 40  | F   | 30.996           | Japan   | Kudo et al.       | 2007 | 0403     |
| 15  | 48  | F   | 885.26           | Japan   | Matsui et al.     | 2007 | 0406     |
| 16  | 45  | F   | 94.997           | Japan   | Yamada et al.     | 2007 | 0403     |
| 17  | 41  | F   | 2047.03          | Japan   | Suzuki et al.     | 2007 | −        |
| 18  | 32  | F   | 17.15            | Japan   | Yoshihiko et al.  | 2007 | 0406     |
| 19  | 71  | F   | 267.84           | Korean  | Chang et al.      | 2009 | 0406     |
| 20  | 70  | F   | 408.98           | Korean  | Bresciani et al.  | 2011 | 0406     |
| 21  | 67  | F   | ≥7.175           | Korean  | Jeong et al.      | 2013 | 0406     |
| 22  | 75  | M   | 1714.83          | Italian | Gullo et al.      | 2014 | 0406     |
| 23  | 77  | F   | 4018             | Italian | Gullo et al.      | 2014 | 0403     |
| 24  | 53  | M   | 2085.43          | Italian | Gullo et al.      | 2014 | 0403     |
| 25  | 40  | F   | 26561.85         | Italian | Gullo et al.      | 2014 | 0403     |
| 26  | 70  | F   | 1607.2           | Italian | Gullo et al.      | 2014 | 0403     |
| 27  | 56  | M   | 2001.83          | Italian | Gullo et al.      | 2014 | 0403     |

Note: The majority of cases reported in the table have been presented exclusively in scientific meetings and were not published.

### Conclusion

Nowadays, ALA therapy is widely used as a dietary and anti-aging supplement or as adjuvant therapy for symptomatic diabetic peripheral neuropathy; it is useful to know that, in patients with a genetic predisposition, this treatment could induce IAS. A prompt diagnosis is required and a targeted
diet should be applied; in some cases a pharmacological therapy in needed.

**Declaration of conflicting interests**
The author(s) declare no potential conflict of interest with respect to the research, authorship and publication of the article.

**Ethics approval**
Our institution does not require ethical approval for reporting individual cases.

**Funding**
The author(s) received no financial support for the research, authorship and/or publication of this article.

**Informed consent**
Informed consent was obtained from the patient for anonymized patient information to be published in this article.

**References**
1. Ismail AA. The insulin autoimmune syndrome (IAS) as a cause of hypoglycaemia: an update on the pathophysiology, biochemical investigations and diagnosis. Clin Chem Lab Med 2016; 54(11): 1715–1724.
2. Lupsa BC, Chong AY, Cochran EK, et al. Autoimmune forms of hypoglycemia. Medicine 2009; 88(3): 141–153.
3. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2009; 94(3): 709–728.
4. Hirata Y and Ishizu H. Elevated insulin-binding capacity of serum proteins in a case with spontaneous hypoglycemia and mild diabetes not treated with insulin. Tohoku J Exp Med 1972; 107: 277–286.
5. Uchigata Y, Hirata Y and Iwamoto Y. Insulin autoimmune syndrome (Hirata disease): epidemiology in Asia, including Japan. Diabetol Int 2010; 1: 21–25.
6. Uchigata Y, Kuwata S, Tokunaga K, et al. Strong association of insulin autoimmune syndrome with HLA-DR4. Lancet 1992; 339(8790): 393–394.
7. Bodansky HJ, Grant PJ, Dean BM, et al. Islet cell antibodies and insulin antibodies in association with common viral infections. Lancet 1986; 2: 1351–1353.
8. Gomez-Cruz MJ, Jabbar M, Saini N, et al. Severe hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in a 16 year old African-American male. Pediatr Diabetes 2012; 13(8): 652–655.
9. Uchigata Y, Hirata Y and Iwamoto Y. Drug-induced insulin autoimmune syndrome. Diabetes Res Clin Pract 2009; 83(1): e19–e20.
10. Li JK, Lee WK, Chan CH, et al. Auto-insulin antibodies due to methimazole in a patient with myasthenia gravis and Graves disease. Ann Gerontol Geriatric Res 2015; 2: 1021–1022.
11. Rouabha S, Ramanoeлина J, Godmer P, et al. Insulin autoimmune syndrome revealing systemic lupus erythematosus. Ann Med Interne (Paris) 2003; 154(1): 59–60.
12. Censi S, Albergoni MP, Gallo N, et al. Insulin autoimmune syndrome (Hirata’s disease) in an Italian patient: a case report and review of the literature. Clin Chem Lab Med 2018; 56(6): 889–895.
13. Gullo D, Evans JL, Sortino G, et al. Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking α-lipoic acid. Clin Endocrinol 2014; 81: 204–209.
14. Matsushima S, Takahashi K, Motoki M, et al. Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and HLA-DRB1*0406 complexes: implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome. J Exp Med 1994; 180: 873–883.
15. Rochette L, Gibbi S, Muresan A, et al. Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Can J Physiol Pharmacol 2015; 93(12): 1021–1027.
16. Uchigata Y. The novel agent, alpha lipoic acid, can cause the development of insulin autoimmune syndrome. Intern Med 2007; 46(17): 1321–1322.
17. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29(11): 2365–2370.
18. Furukawa N, Miyamura N, Nishida K, et al. Possible relevance of alpha lipoic acid contained in an health supplement in a case of insulin autoimmune syndrome. Diabetes Res Clin Pract 2007; 75: 366–367.
19. Takeuchi Y, Miyamoto T, Kakizawa T, et al. Insulin autoimmune syndrome possibly caused by alpha lipoic acid. Intern Med 2007; 46(5): 237–239.
20. Yamada T, Imai J, Ishigaki Y, et al. Possible relevance of HLA-DRB1*0403 haplotype in insulin autoimmune syndrome induced by alpha-lipoic acid, used as a dietary supplement. Diabetes Care 2007; 30(12): e131.
21. Bresciani E, Bussi A, Bazzigaluppi E, et al. Insulin autoimmune syndrome induced by α-lipoic acid in a Caucasian woman: case report. Diabetes Care 2011; 34: e146.
22. Ishida Y, Ohara T, Okuno Y, et al. α-lipoic acid and insulin autoimmune syndrome. Diabetologia 2007; 30(9): 2240–2241.
23. Bae SM, Bae MN, Kim EY, et al. Recurrent insulin autoimmune syndrome caused by α-lipoic acid in types 2 diabetes. Endocrinol Metab 2013; 28: 326–330.
24. Clark PM. Assay for insulin, proinsulin(s) and C-peptide. Ann Clin Biochem 1999; 36: 541–564.
25. Sapin R. Anti-insulin antibodies in insulin immunometric assays: a still possible pitfall. Eur J Clin Chem Clin Biochem 1997; 35(5): 365–367.
26. Gonzalez-Galarza FF, Christmas S, Middleton D, et al. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011; 39: D913–D919.